Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666536 · ClinicalTrials.gov registry record · Phase 4
The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 728
- Enrollment target
NCT00666536: Completed Phase 4 study, sponsored by Novartis.
NCT00666536 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 728 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (41% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666536, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 728 participants
- Enrollment target
Study Summary
The purpose of this trial is to compare blood pressure lowering efficacy of moderate Valsartan + Amlodipine treatment regimen (160 / 5 mg) with that of aggressive regimen (320 / 10 mg) in patients uncontrolled on ARB monotherapy, other than Valsartan
Interventions
- DRUG valsartan and amlodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 728 participants |
| Start Date | 2008-03 |
| Phase | Phase 4 |
What the finished NCT00666536 record still lists
NCT00666536 is an interventional study that assigns participants to a tested intervention. The registered 728 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (41% higher).
The record links to 0 conditions, and to 1 intervention - of which valsartan and amlodipine is the first listed.
NCT00666536 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00666536 about?
NCT00666536 is a clinical study titled "The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy". The purpose of this trial is to compare blood pressure lowering efficacy of moderate Valsartan + Amlodipine treatment regimen (160 / 5 mg) with that of aggressive regimen (320 / 10 mg) in patients uncontrolled on ARB monotherapy, other than Valsartan
What is the current status of trial NCT00666536?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 728 participants. The study started on 2008-03.
What interventions are being tested in trial NCT00666536?
The interventions under investigation include: valsartan and amlodipine (DRUG).
Who is sponsoring clinical trial NCT00666536?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00666536's enrollment target sits among peer trials
728 114th of 2000 higher than 1,887 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- NCT05739123 · 728 participants
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
- NCT06433765 · 728 participants
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
- NCT06660342 · 728 participants
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia